Blood Disease
49
2
2
37
Key Insights
Highlights
Success Rate
95% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.1%
2 terminated out of 49 trials
94.9%
+8.4% vs benchmark
6%
3 trials in Phase 3/4
3%
1 of 37 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 37 completed trials
Clinical Trials (49)
Diamond Blackfan Anemia Registry (DBAR)
Alpha/Beta T-cell Depleted Blood-forming Stem Cell Transplant From Related or Unrelated Donors for Blood Diseases in Children and Young Adults
Examining the Experiences of Children With Blood Disorders
QIAstat-Dx® BCID Plus AMR Panels Clinical Performance Study
Central Nervous System Disorders Following Hematopoietic Stem Cell Transplantation
Role of Transcranial Doppler and Magnetic Resonance Angiography for Future Management of Sickle Cell Anemia CNS.
The Combination of IVIG, Dexamethasone and a Megadose of PBSCs for Decreasing DSAs
Blood Donation--Immune Sequelae and Recruitment
The Evaluation of Anti-interference Ability and Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)
Effect of Recombinant Human Bone Morphogenetic Protein-2 With an Absorbable Collagen Sponge on Stability of Dental Implant: (Split Mouth Randomized Clinical Trial Study.
Collection and Distribution of Biospecimens for Novel Research Uses
Collection and Distribution of Biospecimens for Novel Research
Population Pharmacokinetic-pharmacodynamic Study of Rituximab in Children With Blood Diseases
Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection
HPA Antibodies and the Distribution of Antigen and Antibodies
Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping
Medical Clowning: Needs Assessment and Implication for Hospitalized Children With Cancer/Blood Disease
Delta Hepatitis and Liver Disease in Hemophiliacs
Prevention of Cerebral Infarction in Sickle Cell Anemia - Comprehensive Sickle Cell Center
Cystatin c and Beta 2 Microglobulin in Thalassemic Children.